Drug Profile
Recombinant human insulin - HEC Pharm
Alternative Names: RH InsulinLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Diabetes mellitus
Most Recent Events
- 14 Jun 2019 Recombinant human insulin is still in phase II/III trials for Diabetes mellitus in China (HEC Pharm pipeline, June 2019)
- 25 Aug 2016 Phase-II/III clinical trials in Diabetes mellitus in China (Parenteral) (HEC Pharm pipeline, August 2016)
- 05 Nov 2015 Phase-II clinical trials in Diabetes mellitus in China (Parenteral) (HEC Pharm pipeline, October 2015)